Press coverage about BIOLINERX Ltd/S (NASDAQ:BLRX) has trended positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BIOLINERX Ltd/S earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.80042450557 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- BIOLINERX Ltd/S (BLRX) vs. Vistagen Therapeutics (VTGN) Critical Survey (americanbankingnews.com)
- Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040 (proactiveinvestors.com)
- BIOLINERX Ltd/S (BLRX) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- BIOLINERX Ltd/S (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization (finance.yahoo.com)
Several equities analysts have recently commented on BLRX shares. HC Wainwright set a $4.00 price objective on shares of BIOLINERX Ltd/S and gave the company a “buy” rating in a research note on Tuesday, August 7th. Zacks Investment Research raised shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Friday, May 25th. ValuEngine raised shares of BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, MED started coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They set a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $2.75.
BIOLINERX Ltd/S (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, May 22nd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. equities research analysts anticipate that BIOLINERX Ltd/S will post -0.26 EPS for the current year.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: Should you buy a closed-end mutual fund?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.